CAST (Gene)

Omim:OMIM:114090

Id:78131e8f-9727-515e-9dee-8bb4110bb0c1

Hgnc:HGNC:1515

Entrez:831

Description:calpastatin

The protein encoded by this gene is an endogenous calpain (calcium-dependent cysteine protease) inhibitor. It consists of an N-terminal domain L and four repetitive calpain-inhibition domains (domains 1-4), and it is involved in the proteolysis of amyloid precursor protein. The calpain/calpastatin system is involved in numerous membrane fusion events, such as neural vesicle exocytosis and platelet and red-cell aggregation. The encoded protein is also thought to affect the expression levels of genes encoding structural or regulatory proteins. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jun 2010]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CAST's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CAST.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CAST.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CAST.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CAST.

Results found

Linked to

	Label	Description
	GSE179112 GSE179113 hydroxyl Hutt45 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE118548 trametinib T84 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 10 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE110709 GSK-J4 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE179112 GSE179113 hydroxyl Hutt45 4 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 7 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE118548 trametinib T84 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 10 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 7 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE193993 SSTR2 knockout 0 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE110709 GSK-J4 5 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.